Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lab21 acquires Selah Technologies

Lab21 acquires Selah Technologies

31st December 2009

Lab21, a supplier of diagnostic products and services, has announced its acquisition of Selah Technologies.

The operations of Selah Technologies, which specialises in proprietary nanotechnologies for use in in-vitro and in-vivo diagnostic products, will be incorporated into Lab21.

Additionally, the firm plans to open a new lab next year that focuses on oncology and will include a state-of-the-art diagnostics service laboratory and product distribution operation.

New diagnostic products centred on the specific carbon-based, non-toxic, enhanced fluorescent nano-particle technology will also be established, the firm revealed.

Graham Mullis, chief executive officer of Lab21, stated: “The acquisition of Selah Technologies is a key step in the development of Lab21’s strategy as we look to expand our technology platforms as well as our global commercial operations.”

Meanwhile, Lab21 announced another acquisition earlier this month – that of Delphic Diagnostics.

The firm, which went into administration, has bases in Liverpool and Kent and specialises in companion diagnostics and personalised medicine for pharmacology, therapeutic drug monitoring, virology and specialist clinical trial services.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.